Outbrain (OB) and Brainsway (BWAY) Are Aggressive Growth Stocks

As the aggressive growth stock strategist at Zacks Investment Research Brian Bolan usually looks for stocks that have a strong Zacks Style Score for Growth and a weak Style Score for Value. This week he is using his noodle to come up with two smart stock picks. Brian jokes that he has “brain bamage” but this is no laughing matter as these stock are aggressive growth picks.Outbrain OB is a Zacks Rank #1 (Strong Buy) and it has an A for Growth and an A for Value. This recommendation engine helps advertisers connect with consumers on their favorite media sources. Brian notes that this was a selection in the Stocks Under $10 service that he manages for Zacks Investment Research but fails to point out that the investment was short lived and was sold for a small loss.Brainsway BWAY is a Zacks Rank #1 (Strong Buy) and has a A for Growth and a B for Value in the Zacks Style Scores. The company is in the medical products space and has a proprietary Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder.Just as in all of his Aggressive Growth Zacks Rank Buy videos, Brian reviews the earnings history, earnings estimates, growth projections and valuation before taking a look at the chart.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Outbrain Inc. (OB): Free Stock Analysis Report Brainsway Ltd. Sponsored ADR (BWAY): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks